乳腺肿瘤DNA含量及雌激素受体的测定  

ASSAY 0F DNA CONTENT AND ESTROGEN RECEPTOR STATUS IN HUMAN BREAST CANCER

作　　者：陈国际[1] 邵永孚[1] 单毅[1] 

机构地区：[1]中国医学科学院,中国协和医科大学肿瘤医院腹部外科

出　　处：《中华肿瘤杂志》1994年第6期461-464,共4页Chinese Journal of Oncology

摘　　要：应用流式细胞分析仪检测乳腺癌（４２例）、乳腺纤维腺瘤（１０例）、乳腺囊性增生病（１０例）及正常乳腺组织（１０例）的细胞ＤＮＡ含量。４２例乳腺癌标本中，２６例（６２％）为异倍体ＤＮＡ；乳腺囊性增生病和正常乳腺组织均为二倍体ＤＮＡ。乳腺癌标本均行雌激素受体（ＥＲ）测定，１１例（２６％）为阴性。同时对所有乳腺癌进行有关临床资料和病理分析，发现乳腺癌ＤＮＡ含量与病人年龄及ＥＲ状态差异均有显著性意义（Ｐ＜０．０５）。乳腺肿瘤细胞周期分析发现异倍体癌Ｓ期细胞比率最高。通过乳腺癌细胞ＤＮＡ含量及ＥＲ测定，计算细胞增殖周期中各期细胞比率，可以判断乳腺癌生物学特性，为患者预后的评估提供客观、定量和可重复性参数，弥补形态学检查的不足，并对术后辅助治疗有指导意义。Abstract Cellular DNA content of 72 samples was analyzed by flow cytometry. The results showed that20 benign tumors and l0 normal breast tissue specimens were found to be DNA diploidy. 26(62%) of 42 cases of breast cancer were DNA aneuploidy and the remainders were DNA diploidy. The median s- phase cell percentage was significantly higher in aneuploid tumors (28 %) thandiploid tumors (13%)and benign tumors (4%). Estrogen receptors were also investigated in 42 breastcancer specimens. There were 31 ER positive (74%) cases and 11 negative(26%) cases. The aneuploid DNA content was usually associated with lack of estrogen receptors. DNA con-tent correlated significantly with age and ER status. The results suggest that flow cytometric analysis of aillular DNA content of breast cancer and status of estrogen receptors can provide an objective quantitative and reproducible new parameter for predicting prognosis of breast cancer.

关 键 词：乳腺癌 DNA 分析 雌激素 受体 流式细胞术 

分 类 号：R737.902[医药卫生—肿瘤]